Page 73 - Let them speak Towards a patient reported outcome measure set for

Protocol for developing a core PRO set
References
1. Castrén E, Elgersma Y, Maffei L, Hagerman R. Treatment of neurodevelopmental disorders in
adulthood. Journal of Neuroscience. 2012;32(41):14074-9.
2. Levy G, Barak B. Postnatal therapeutic approaches in genetic neurodevelopmental disorders.
Neural Regeneration Research. 2021;16(3):414.
3. (EURORDIS) EOfRD. The voice of rare disease patients in Europe. 2017.
4. Genes G. Rare diseases: facts and statistics. Statistics and Figures on Prevalence of Genetic
and Rare Diseases Available at: https://globalgenes org/rare-diseases-facts-statistics/
Accessed. 2017;5.
5. Swillen A, McDonald‐McGinn D, editors. Developmental trajectories in 22q11. 2 deletion
syndrome. American Journal of Medical Genetics Part C: Seminars in Medical Genetics; 2015:
Wiley Online Library.
6. Juriaans AF, Kerkhof GF, Hokken-Koelega AC. The spectrum of the Prader–Willi-like pheno-and
genotype: a review of the literature. Endocrine Reviews. 2022;43(1):1-18.
7. Salcedo-Arellano MJ, Hagerman RJ, Martínez-Cerdeño V. Fragile X syndrome: clinical
presentation, pathology and treatment. Gac Med Mex. 2020;156(1):60-6.
8. Patel DR, Merrick J. Neurodevelopmental disabilities: Introduction and epidemiology.
Neurodevelopmental disabilities: clinical care for children and young adults. 2011:1-13.
9. Wang J, Wang Y, Wang L, Chen WY, Sheng M. The diagnostic yield of intellectual disability:
combined whole genome low-coverage sequencing and medical exome sequencing. BMC
medical genomics. 2020;13:1-15.
10. Maia N, Nabais Sá MJ, Melo-Pires M, de Brouwer AP, Jorge P. Intellectual disability genomics:
current state, pitfalls and future challenges. BMC genomics. 2021;22(1):1-17.
11. Pekeles H, Accogli A, Boudrahem-Addour N, Russell L, Parente F, Srour M. Diagnostic yield of
intellectual disability gene panels. Pediatric neurology. 2019;92:32-6.
12. Butcher NJ, Chow EW, Costain G, Karas D, Ho A, Bassett AS. Functional outcomes of adults
with 22q11. 2 deletion syndrome. Genetics in medicine. 2012;14(10):836-43.
13. Williams K, Jacoby P, Whitehouse A, Kim R, Epstein A, Murphy N, et al. Functioning, participation,
and quality of life in children with intellectual disability: an observational study. Developmental
Medicine & Child Neurology. 2021;63(1):89-96.
14. McGuire BE, Defrin R. Pain perception in people with Down syndrome: a synthesis of clinical
and experimental research. Frontiers in behavioral neuroscience. 2015;9:194.
15. Robertson J, Hatton C, Emerson E, Baines S. Prevalence of epilepsy among people with
intellectual disabilities: a systematic review. Seizure. 2015;29:46-62.
16. Lubbers K, Stijl EM, Dierckx B, Hagenaar DA, Ten Hoopen LW, Legerstee JS, et al. Autism
symptoms in children and young adults with fragile x syndrome, angelman syndrome,
tuberous sclerosis complex, and neurofibromatosis type 1: a cross-syndrome comparison.
Frontiers in Psychiatry. 2022;13:852208.
17. Arron K, Oliver C, Moss J, Berg K, Burbidge C. The prevalence and phenomenology of self‐
injurious and aggressive behaviour in genetic syndromes. Journal of Intellectual Disability
Research. 2011;55(2):109-20.
18. Cooper S-A, McLean G, Guthrie B, McConnachie A, Mercer S, Sullivan F, Morrison J. Multiple
physical and mental health comorbidity in adults with intellectual disabilities: population-
based cross-sectional analysis. BMC family practice. 2015;16:1-11.
19. Health USDo, Human Services FDACfDE, Research, Health USDo, Human Services FDACfBE,
Research, et al. Guidance for industry: patient-reported outcome measures: use in medical
product development to support labeling claims: draft guidance. Health and Quality of Life
Outcomes. 2006;4(1):79.
20. McKenna SP. Measuring patient-reported outcomes: moving beyond misplaced common
sense to hard science. BMC medicine. 2011;9(1):1-12.
21. Varni JW, Burwinkle TM, Seid M, Skarr D. The PedsQL 4.0 as a pediatric population health
measure: feasibility, reliability, and validity. Ambulatory Pediatrics. 2003;3(6):329-41.
3
71